PD-L1 immunohistochemical test

PD-L1 immunohistochemistry test FDA approved therapy (05-June-2020)

Immuno-oncology trends can be followed through portals in Cancer Research Institute (New York), Keytruda: pathologist centre and staining examples in lung cancers can be found in the IASLC Color Atlas.

Tumors	Positive
Lung Cancers	High: TPS>=50%
Lung Cancers	Low: TPS 1-49%
H&N SCC	CPS>=1
Esophagus/EGJ carcinoma	CPS>=10
Stomach carcinoma	CPS>=1 (not sure)
Cervical Cancers	CPS>=1
Triple Negative Breast Cancer	CPS>=10
All other	CPS>=1

Analytical details:

- Tumor cells (%) : (with membrane signals > or = 1+ among 100 tumor cells)
	- Further details :
- Immune cells among the tumor (%): (any types of signals > or = 1+)
	- Positive immune cells among immune cells (%) :
- Antibody (anti-PD-L1, anti-CD274) :
- Number of viable tumor cells :
- Fixation time in buffered formalin :

PD-L1 scoring:

- Tumor Proportion Score (TPS) % :
- Combined Positive Score (CPS) :

- Tumor Proportion Score (TPS) % :
- Combined Positive Score (CPS):

Positive percentage
(from Roche document SP263 manual)